MedTrace Logo

Effectiveness of Contingency Management in the Treatment of Crack Addiction in Brazil

NCT03345394 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2021-04-08

Study results available
· View outcomes & findings →

Summary

Crack addiction has become a severe public health problem in Brazil. Crack users present elevated prevalence rates of psychiatric comorbidities, sexual transmitted infections and unemployment with high probability of living or have lived in the streets, history of incarceration and engagement in illegal activities. For the last 20 years a treatment called Contingency Management (CM) have achieved the best results regarding reduction of substance use, promotion of abstinence, treatment attendance and retention in treatment. The first CM study conducted in Brazil advocates for the efficacy of CM on all of these outcomes, suggesting that CM can be effective in a Brazilian population of crack users.

Conditions

Interventions

BEHAVIORAL

Contingency Management

Participants will receive vouchers with monetary value for submitting crack cocaine negative urine samples

BEHAVIORAL

Standard treatment

Participants will receive the standard treatment offered at Unidade Recomeço Helvétia treatment program

Sponsors & Collaborators

  • Washington State University

    collaborator OTHER

  • Federal University of São Paulo

    lead OTHER

Principal Investigators

  • Andre M de Queiroz Constantino Miguel, PhD · Federal University of São Paulo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2020-12-01
Completion
2020-12-01

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03345394 on ClinicalTrials.gov